The treatment of Hodgkin's Lymphoma (HL) has significant historical importance in the field of medical oncology. Despite being a rare malignancy, HL has represented a model for oncologic advances. HL was one of the first oncologic illnesses proved to be potentially medically cured. Radiation therapy has long been known to be curative for the majority of patients with limited stage HL. Additionally, the concept of dose intensity was demonstrated to have clinical validity in patients with HL, as a clear dose response curve in radiation therapy dose has been demonstrated. Combination chemotherapy is potentially curative for patients with advanced stage HL and represents a paradigm for combining different effective chemothera-peutic agents in a single regimen. More recently, long-term toxicities and complications of therapy, including secondary cancers, significant organ damage, and other toxicities, have been demonstrated in patients presumably cured from their HL as a result of therapy. Late toxicities have generated a spirited debate in recent years of the optimal way to treat classical HL. This chapter will present the "standard" recommendations for the treatment of HL and will also present a contrarian viewpoint.

0 0

Post a comment